Laura Joszt, MA

The GOLD International COPD Conference will cover underdiagnosis, exacerbations, mucus, biologics, and a preview of the 2027 GOLD Report.

Mary Caffrey, executive editor of AJMC, interviews Patty and Brian Koffman, MDCM, on why caregivers are critical to outpatient CAR T-cell therapy and bispecific antibody access.

Oncologists reveal why breakthrough cancer drugs still stall—referral gaps, payer delays, caregiver needs, and pharmacy bottlenecks reshape access across tumor types.

Experts at ASN Kidney Week say earlier detection, national CKD screening, and faster uptake are needed to bring new therapies to patients.

Cost and access, not side effects, drive GLP-1 discontinuation, and obesity should be covered like diabetes, says Fatima Cody Stanford, MD.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH

NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.

Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.

Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.

Sparsentan cut proteinuria about 70% and kept kidney function stable over 2 years in newly diagnosed IgA nephropathy in the SPARTAN study.

Medicare’s GLP-1 Bridge program aims to expand obesity treatment, but eligibility hurdles and drug costs leave many seniors paying hundreds monthly.

AI, patient voice in pathways, and caregiver support are shaping community oncology, AON leaders said at Patient-Centered Oncology Care.

Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.

Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

AI, patient voice in pathways, and caregiver support are shaping community oncology, AON leaders said at Patient-Centered Oncology Care.

Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.

Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.

Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.

Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.

The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.

Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.

Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.

Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.

A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.

Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.